RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
214 hedge funds and large institutions have $3.27B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 78 increasing their positions, 71 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
214
Holders Change
-4
Holders Change %
-1.83%
% of All Funds
4.73%
Holding in Top 10
10
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-41.18%
% of All Funds
0.22%
New
33
Increased
78
Reduced
71
Closed
33
Calls
$129M
Puts
$56.6M
Net Calls
+$72M
Net Calls Change
-$45.9M
Top Buyers
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$61.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$47.5M |
| 3 |
SPC
Slate Path Capital
New York
|
-$24.5M |
| 4 |
Renaissance Technologies
New York
|
-$19.8M |
| 5 |
BlackRock
New York
|
-$17.4M |
